Clinical trial
An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus: A 24-week, Multi Center, Randomized, Double-blind, Parallel-group, Placebo Control, Therapeutic Confirmatory Study
NCT01001611 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus: A 24-week, Multi Center, Randomized, Double-blind, Parallel-group, Placebo Control, Therapeutic Confirmatory Study
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- January 31, 2012
- Enrollment
- 173 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.